ADIL Stock — Adial Pharmaceuticals Inc

Adial Pharmaceuticals Inc (ADIL)

Updated October 16, 2026.

ADIL is a Stock. Total return is -99.9% over the past 8.2 years, 307.0 points behind SPY at 207.1%.

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics for addiction and related disorders, with its lead candidate AD04 currently in Phase 3 trials for alcohol use disorder treatment. The company does not currently have an established distribution schedule. This security is oriented toward investors focused on clinical-stage biotech development risk and potential therapeutic breakthroughs rather than current income generation.

ADIL performance versus SPY

Price and return data through 2026-10-16.

Total return is -99.9% over the past 8.2 years, 307.0 points behind SPY at 207.1%. Over the past year its total return — price change plus distributions reinvested — is -62.5%. Its deepest 1-year drawdown was 85.6%.

ADIL key facts

Asset type

Stock

Asset class

Equity

Inception date

07/27/2018

Distribution frequency

None

Last close

$3.49 (as of 2026-10-16)

Market cap

$9,164,356

Average volume

56359.0

Beta

1.503

Payout ratio

0.0%

EPS

$-18.89

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

ADIL risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 85.6%.

Who may consider ADIL — and who may not

It is a weaker fit for investors who need monthly cash flow (ADIL does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on ADIL

• All tickers starting with A

Tagged: Healthcare.

Frequently asked questions